AngioDynamics (Nasdaq:ANGO) announced that it completed the sale of its dialysis product portfolio to Merit Medical Systems.
It was part of a series of product acquisitions worth $132.5 million that Merit (Nasdaq: MMSI) has announced.
Latham, New York-based AngioDynamics sold its dialysis portfolio and the BioSentry product for $100 million in cash. The transaction includes the DuraFlow, DuraMax, Evenmore, Schon XL, Trio-CT and Vaxel Plus hemodialysis catheter brands. It also includes the BioSentry product, a tract sealant system biopsy brand.
AngioDynamics said in a news release that the combined product portfolio generated $32 million in sales in 2023.